Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda

•HIV+ individuals are an important subpopulation in areas at risk of an Ebola outbreak.•The Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen induced antibodies that persisted 4·5 years.•Ad26.ZEBOV booster dose is safe and highly immunogenic in previously immunized HIV+ adults.•Ad26.ZEBOV boosters can be deployed safely to HIV+ adults with well-controlled infection.